The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro
Open accessAbstract
Bryostatin is a unique lead in the development of potentially transformative therapies for cancer, Alzheimer’s disease, and the eradication of HIV/AIDS. However, the clinical use of bryostatin has been hampered by its limited supply, difficulties in accessing clinically-relevant derivatives, and side effects. Herein, we address these problems through the step-economical syntheses of seven members of a new family of designed bryostatin analogues utilizing a highly convergent Prins-macrocyclization strategy. We also demonstrate for the first time that such analogues effectively induce latent HIV activation in vitro with potencies similar to or better than bryostatin. Significantly, these analogues are up to 1000-fold more potent in inducing latent HIV expression than prostratin, the current clinical candidate for latent virus induction. This study provides the first demonstration that designed, synthetically-accessible bryostatin analogues could serve as superior candidates for the eradication of HIV/AIDS through induction of latent viral reservoirs in conjunction with current antiretroviral therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
Mills, E. J., Nachega, J. B., Bangsberg, D. R., Singh, S., Rachlis, B., Wu, P., Wilson, K., Buchan, I., Gill, C. J., & Cooper, C. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030438 · Cited by 818
Bryostatin-1: A novel PKC inhibitor in clinical development
Kortmansky, J., & Schwartz, G. K. (2003) · Cancer Investigation · doi:10.1081/cnv-120025095 · Cited by 183
Cited by
Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2014) · Nature Medicine · doi:10.1038/nm.3489 · Cited by 488
Spina, C. A., Anderson, J., Archin, N. M., Bosque, A., Chan, J., Famiglietti, M., Greene, W. C., Kashuba, A., Lewin, S. R., Margolis, D. M., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003834 · Cited by 403
Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
Laird, G. M., Bullen, C. K., Rosenbloom, D. I. S., Martin, A. R., Hill, A. L., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80142 · Cited by 391
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends: Miniperspective
Zhan, P., Pannecouque, C., De Clercq, E., & Liu, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00497 · Cited by 303
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs
Katlama, C., Deeks, S. G., Autran, B., Martinez-Picado, J., van Lunzen, J., Rouzioux, C., Miller, M., Vella, S., Schmitz, J. E., Ahlers, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60104-x · Cited by 295
Metadata
- Authors
- DeChristopher, B. A., Loy, B. A., Marsden, M. D., Schrier, A. J., Zack, J. A., & Wender, P. A.
- Venue
- Nature Chemistry
- Published
- 2012-07-15
- Volume
- 4
- Issue
- 9
- Pages
- 705-710
- ISSN
- 1755-4330 (ISSN-L)
- 1755-4349
- OpenAlex
- W2081224837
- Cited by
- 161
- References
- 3
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. https://app.cochat.ai/papers/10.1038/nchem.1395
- The paper
- DeChristopher, B. A., Loy, B. A., Marsden, M. D., Schrier, A. J., Zack, J. A., & Wender, P. A. (2012). Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nature Chemistry. https://doi.org/10.1038/nchem.1395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.